Glaucoma affects 1% of people over the age of 40 years 1,2 . Patients with this diagnosis account for about 15±25% of ophthalmic hospital outpatient visits and make up a substantial proportion of the ophthalmologist's workload 3 . The demand will increase in the future because of ageing in the population combined with improved community screening and increased awareness among the public 4 .
The principal form of glaucoma in the UK is primary open angle glaucoma (POAG). This condition has an insidious onset, most patients being unaware of their disease despite in many cases moderate to severe visual ®eld loss. The aim of treatment is to prevent further visual loss, or at least to prevent disabling visual loss during the patient's lifetime. A study from the United States, in a predominantly Caucasian population, showed that about 22% of patients with POAG developed blinding visual loss over a 20-year period despite treatment 5 . One risk factor for progression to blindness is late presentation 6 , and in the UK factors contributing to late presentation include Afro-Caribbean origin (these patients are more than four times more likely than white patients to present with advanced disease), old age, male sex, and referral from sources other than an optician 7 .
ADVANCES IN DIAGNOSIS
One way to prevent late presentation would be to identify individuals carrying a glaucoma gene. The most common mutation so far discovered has been in the Trabecular meshwork Induced Glucocorticoid Response (TIGR) gene 8,9 . In families with a member affected by glaucoma, individuals shown to be at risk by genetic testing could be carefully followed up and offered early treatment if necessary. Genetic screening raises dif®cult ethical issues, but an Australian study indicated that relatives of glaucoma patients generally wished to know their risk of developing the disease 10 . However, we are still a long way from identifying mutations that account for most of the glaucoma seen.
With the ever-increasing mass of glaucoma sufferers and the need for regular review in a busy hospital service, methods for dealing with glaucoma in the community are being examined. In Bristol a shared-care scheme has been piloted to examine the feasibility of optician-based glaucoma review services. Trained community-based optometrists were shown to be reliable in measuring factors important in the assessment of glaucoma patients 11, 12 Ða ®nding with practical as well as cost implications for the future of glaucoma management.
The primary methods for diagnosing and monitoring the progression of glaucomatous damage to the optic nerve are visual ®eld testing and optic disc examination. Automated threshold perimetry provides a subjective assessment of the intensity of light seen by a patient at prede®ned points in the visual ®eld. Automated perimetry can be timeconsuming and tedious, especially for the elderly; testing each eye's visual ®eld can take 14±15 minutes 13 . Recently, the algorithm used for threshold perimetry has been modi®ed: the Swedish interactive threshold algorithm performs the visual ®eld test in half the time without any loss of information, allowing substantially more visual ®eld testing to be done 13±16 . Another development has been short wave automated perimetry (SWAP), which uses a blue target stimulus on a yellow background and identi®es glaucomatous defects earlier than conventional perimetry 17 . Unfortunately, SWAP is adversely affected by cataract, a serious drawback in the elderly population primarily affected by glaucoma 18 .
There is evidence that, in patients with glaucoma, considerable damage to the optic nerve has occurred before visual ®eld loss becomes detectable 19, 20 Ðhence the development of techniques that directly examine the optic nerve head and surrounding nerve ®bre layer 21±23 . One of these is the Heidelberg retina tomograph, a confocal scanning laser ophthalmoscope that quanti®es speci®c optic nerve-head and retinal nerve ®bre layer characteristics; this device has been shown to detect optic nerve damage in early glaucoma 24 , identifying change at the nerve head before con®rmed visual ®eld loss 25 . Since image acquisition takes only a few seconds and provides an objective assessment of the optic nerve, this technique could ®nd a place in screening for glaucoma and monitoring of those affected.
ADVANCES IN THERAPY
The concept of intraocular pressure control in glaucoma has changed: it is no longer considered adequate to reduce pressure to within the normal range. Instead, the clinician de®nes a`target pressure' in each patient at which further glaucomatous damage is deemed unlikely. Generally, the more severe the glaucoma damage and the lower the presenting intraocular pressure, the lower the target pressure required 26 .
Topical medications remain the primary method of treatment. While beta-blockers are the initial choice in most patients (if no contraindications exist), second-line therapy is evolving with the introduction of several new topical preparations. Dorzolamide (Trusopt) is a carbonic anhydrase inhibitor 27 , brimonidine (Alphagan) an alpha agonist 28 and latanoprost (Xalatan) a prostaglandin analogue 29 . The systemic side-effect pro®le of these newer treatments is better than that of the beta-blockers, and they are suitable choices in patients for whom beta-blockers are contraindicated 30 . A combination preparation of timolol and dorzolamide (Cosopt) has also been introduced in an attempt to lower intraocular pressure further by dual action 31 .
There is some evidence that treatment of POAG by primary trabeculectomy gives a better long-term visual outcome than laser or medical treatment 32 ; if so, this is probably because it is more effective in lowering intraocular pressure. When such`®ltration surgery' fails, the usual reason is scar tissue at the operation site.
Risk factors for surgical failure include Afro-Caribbean race, previous ocular surgery, long-term use of topical antiglaucoma medications (particularly pilocarpine and adrenergic agents), aphakia, rubeosis and young age. Attempts have been directed towards perioperative modulation of wound healing and postoperative modulation of scar formation 33 . Perioperative modulation usually consists of application of an antiscarring agent such as 5-¯uorouracil or the more potent mitomycin C at the operation site. These agents reduce postoperative ®brosis 33 . An alternative approach is to apply beta-irradiation, which similarly dampens the healing response 34 .
For some patients`bleb failure' becomes apparent in the postoperative period. The bleb under the conjunctiva is caused by drainage of aqueous humour from the anterior chamber. In such cases needling can be helpful: a small gauge needle is inserted into the bleb and, with a gentle but ®rm sweeping action, used to break down ®brous tissue at the ®ltration site and re-establish drainage. This needling is often accompanied by the injection of an anti-metabolite (usually 5-¯uorouracil) to prevent recurrence of scar formation 35, 36 . The downside of anti-metabolite treatment is an increased risk of late postoperative complications such as wound leakage and intraocular infection.
Another way to improve postoperative drainage from the trabeculectomy is to use releasable scleral¯ap sutures. Specially designed releasable sutures are available, but an alternative is to release ®xed¯ap sutures by means of an argon laser. This is best done before¯ap ®brosis has occurred, usually within three weeks for unaugmented trabeculectomies and three months for mitomycin trabeculectomies 37, 38 .
While trabeculectomy remains the commonest surgical treatment for glaucoma, surgical technique has been modi®ed to reduce complications such as intraocular infection and postoperative hypotony. Non-penetrating methods will include visco-canalostomy 39 and deep sclerectomy 39 . Longer follow-up and randomized controlled trials are needed before we know whether the initial enthusiasm for these techniques is justi®ed.
Another way to reduce intraocular pressure is to destroy the ciliary body, either by laser probes applied externally to the sclera, which focus energy to the region of the ciliary body and produce tissue disruption of the aqueous producing cells, or by intraocular probes with endoscopic viewing of the ciliary processes 40, 41 . The latter technique allows more accurate treatment of the ciliary body and reduces the risks of overtreatment or undertreatment that are drawbacks of the other forms of cyclodestructive therapy. This technique is usually reserved for patients in whom other forms of treatment have failed or whose visual potential is poor.
CONCLUSION
In summary, the diagnosis, monitoring and treatment of glaucoma continue to evolve. We can expect the quicker techniques for screening, earlier diagnosis and better methods for lowering intraocular pressure to make a large and bene®cial impact on loss of vision associated with this disease.
J O U R N A L O F T H E R O Y A L S O C I E T Y O F M E D I C I N E
V o l u m e 9 3 A p r i l 2 0 0 0
